Respiratory safety of weight-loss drugs

A systematic review and meta-analysis published in the Annals of the American Thoracic Society on 21 July 2026 examined respiratory adverse events across 123 randomised and non-randomised studies of seven weight-loss drug classes, including semaglutide, tirzepatide, liraglutide, orlistat, naltrexone-bupropion, phentermine-topiramate, and setmelanotide. The headline finding: four of these medications showed no evidence of increased respiratory harm compared with placebo^[1].

Respiratory adverse events matter in this context because obesity and asthma frequently coexist, and clinicians regularly prescribe these drugs to patients who already carry a respiratory diagnosis. The review, led by Lijuan Zeng and colleagues at Johns Hopkins, screened 9,086 records and built its conclusions on 122 general-population studies plus one asthma-specific study^[1].

What the meta-analysis found

Nasopharyngitis was the most consistently measured respiratory outcome across the included studies. Incidence rates varied widely across drug classes: 4.1% (95% CI: 0.7%-9.3%) for tirzepatide and up to 23.7% (95% CI: 19.6%-28.1%) for liraglutide^[1]. The researchers note that rates within each drug were not clearly dose-dependent, which matters for interpreting the clinical relevance of any signal.

The overall picture for the four major agents studied was characterised by the authors as a "reassuring respiratory safety profile" in general populations. Upper respiratory events were common but were not elevated above comparator rates in the available controlled data. This finding is broadly consistent with an earlier 2026 systematic review of GLP-1 receptor agonists specifically, which similarly concluded that upper respiratory tract infections occurred at rates comparable to control groups^[2].

The gap the study identifies

The more significant finding may be what the 123 included studies could not answer. Despite the high prevalence of obesity-asthma comorbidity, only one of the 123 studies enrolled participants specifically selected for asthma. The authors write that evidence addressing individuals with asthma and respiratory disease remains limited, and they call this a critical knowledge gap given that many patients in clinical practice carry both diagnoses simultaneously^[1].

This gap is not trivial. Obesity worsens asthma control through mechanical load on the chest wall, systemic inflammation, and changes in airway geometry. Weight loss by any mechanism tends to improve asthma outcomes. Whether the specific pharmacological effects of GLP-1 agonists, tirzepatide, or other weight-loss drug classes add to, or subtract from, that mechanical benefit is simply not yet known from controlled data.

What this means for the drug classes covered

For semaglutide and tirzepatide, the reassuring general-population picture is consistent with prescribing information, which does not carry specific respiratory warnings beyond the perioperative aspiration risk shared across GLP-1 class agents. The gastric-emptying delay that all GLP-1 drugs produce raises aspiration risk under anaesthesia, and that concern applies regardless of whether the respiratory safety profile in general populations is benign. Patients scheduled for surgery should discuss their GLP-1 or dual-agonist use with their anaesthetist before any procedure.

For liraglutide, the higher observed nasopharyngitis incidence (23.7%) warrants attention, though the review notes this is not clearly dose-dependent and the mechanism is uncertain. A separate 2026 systematic review comparing tirzepatide with GLP-1 mono-agonists found that liraglutide carried a higher overall adverse-event burden than either semaglutide or tirzepatide, consistent with its older pharmacological profile and higher clinical exposure at the doses studied^[3].

What the study does not settle

The authors are explicit that the general-population reassurance should not be read as clearance for patients with established respiratory disease. The single asthma-specific study in the dataset is not sufficient to draw clinical conclusions about GLP-1 or weight-loss drug safety in that population. Anyone with asthma, chronic obstructive pulmonary disease, or another respiratory diagnosis who is considering or currently taking one of these drugs should discuss the specific evidence gap with their prescriber.

Causality also remains unresolved for the serious respiratory events that have appeared in the pharmacovigilance and case-report literature. Anaphylaxis with bronchospasm, acute eosinophilic pneumonia, and aspiration-related events have been documented in temporal association with GLP-1 class drug use, but the evidentiary standards of a systematic review cannot establish causation from case-level data. The ATS review adds to, rather than resolves, the picture.

Where this sits on the site

Readers interested in a deeper look at adverse-event signals specific to GLP-1 receptor agonists can find the earlier June 2026 systematic review on our coverage of GLP-1 drugs and lung safety. For the broader side-effect profile of semaglutide and tirzepatide, including gastrointestinal and cardiovascular signals, see the individual peptide pages. The medical disclaimer below applies: this article is educational and journalistic in intent and does not substitute for a conversation with a clinician who knows your individual respiratory history.